Anxiety
Pipeline by Development Stage
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
30 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 21,817 patients across 50 trials
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
Effects of Xiangshao Granules on Anxiety in Menopausal Women.
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders
Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery
A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
Duloxetine vs Placebo in the Treatment of General Anxiety
A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety
Individual and Family Therapy for Children With Anxiety Disorders
Cannabidiol for Anxiety
Comparison of MMFS Dosages in Older Adults
"The Evaluation of Stimulant Withdrawal"
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg
Personalizing Mental Health Treatment for Youth and Families
By Youth, For Youth: Digital Supported Peer Navigation for Addressing Child Mental Health Care
Bonding Before Birth: A mHealth Intervention for First-time Expectant Couples
Effect of Virtual Reality Use on Preoperative Anxiety
Implementation of DWM in Dutch SMEs
Transforming Health and Reducing Perinatal Anxiety Through Virtual Engagement
Rare Group Problem Management Plus
Peer Support Groups for Families With an Infant in the NICU
Do Mind Ease Interventions Reduce Feelings of Acute Anxiety? A Randomised Controlled Trial
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety: A Randomized Clinical Trial
Prospective, Multi Centric, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KSM-66 Ashwagandha (Withania Somnifera) in Adults Experiencing High Stress and/or Anxiety
Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety
Effects of Virtual Reality MRI Preparedness
School-Based Treatment for Early Childhood Anxiety
The Moving 2 Mindful (M2M) Study: Mindfulness Group + Ecological Momentary Intervention
Breathing for Adolescent Stress Reduction Feasibility RCT
A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study
Happy Mother - Healthy Baby: Supplement Study on Biological Processes Underlying Anxiety During Pregnancy
Using Virtual Reality Simulation to Prepare Children Undergoing MRI
CALM for Pregnant and Post-Partum Women
Wait List Controlled Trial of Brief ACT and Brief MBSR-informed Group Interventions for Anxiety in a University Setting
Evaluation of the Medical Psychiatry Alliance Senior's Outpatient Collaborative Care Project
Anxiety, Inflammation, Stress, and Cannabinoids
Experiential Training for Community Therapists
StriveWeekly: Self-Guided Online Intervention for Anxiety, Depression, and Stress in University Students
Attention Training for Underserved Youth With Anxiety
Clinical and Cost Effectiveness of Alpha-Stim AID CES
Effectiveness of CES on Emotional and Cellular Wellbeing
Negative-Positive Valence Domains in Anxiety and Depression
Structured Information During the Intensive Care Unit Stay
Comorbidity Between Balance and Childhood Anxiety
Related Jobs in Neurology
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Associate Director, Operational Procurement
Sales Support Representative (Temp-to-Hire)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.